Is Dyne Therapeutics (NASDAQ:DYN) Slipping 8.98% Ahead of Its January FDA Date?

Vinay Lochav

04 November 2026 11:32 PM AEDT

Is Dyne Therapeutics (NASDAQ:DYN) Slipping 8.98% Ahead of Its January FDA Date?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Dyne Therapeutics shares dropped 8.98% to USD 16.43 in premarket trading on November 4, 2026.
The FDA target action date for z-rostudirsen in exon 51 Duchenne is January 21, 2027, under Priority Review.
Cash and marketable securities stood at USD 898.5 million at June 30, 2026, before a July offering of about USD 431 million gross.
The second quarter 2026 net loss was USD 178.6 million, or USD 1.08 per share, versus USD 110.9 million a year earlier.
No company announcement dated November 2 to November 4, 2026 was identified.

What Moved Dyne Therapeutics Before the Open (down USD 1.62, 8.98%)

Dyne Therapeutics (NASDAQ:DYN) was down 8.98% at USD 16.43 in premarket trading on November 4, 2026, a fall of USD 1.62 from the Tuesday, November 3, 2026 close. That implies a prior close of about USD 18.05, a figure calculated from the screen data.

No press release or regulatory filing dated November 2 to November 4, 2026 was identified as a catalyst, and the company has not confirmed a date for its third quarter report. With no company news in view, the move looks like sentiment or sector driven trading in a clinical-stage biotech ahead of a binary regulatory event.

What Is the Pipeline Backdrop?

Dyne's lead program, z-rostudirsen (also called DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, had its Biologics License Application accepted with Priority Review in July 2026. The target action date is January 21, 2027, and the company expects a potential United States launch in the first quarter of 2027.

In the December 8, 2025 Phase 1/2 DELIVER results, the company reported muscle content adjusted dystrophin expression of 5.46% of normal at six months on the 20 mg/kg every four weeks dose, a statistically significant change from baseline. Across 86 participants, most related adverse events were mild or moderate, with fever and headache the most common, and no related serious adverse events occurred in the placebo controlled portion.

The second program, z-basivarsen (DYNE-101) for myotonic dystrophy type 1, completed enrollment of 71 participants in its registrational expansion cohort in June 2026. Topline data are planned for the first quarter of 2027, with a potential Accelerated Approval submission in the third quarter of 2027.

What Do the Latest Results Show?

In its July 29, 2026 Earnings update, Dyne reported second quarter Research and Development expense of USD 152.2 million, up from USD 99.2 million a year earlier. General and administrative expense rose to USD 29.5 million from USD 16.6 million as the company prepared for a possible launch.

The net loss widened to USD 178.6 million, or USD 1.08 per share, from USD 110.9 million, or USD 0.97 per share.

What Are the Balance Sheet and Risks?

Dyne held USD 898.5 million in cash, cash equivalents and marketable securities on June 30, 2026. In July 2026, it sold 21,045,000 shares at USD 20.50, raising about USD 431 million gross and about USD 405.0 million net. The company said this funds operations into the second quarter of 2028.

Risks include the regulatory outcome in January 2027, small patient numbers in the functional analyses, rising launch costs and the dilution already seen in the July offering, which was priced above the current premarket level.

What to Watch Next

Key items are the third quarter report, which one data aggregator estimates for around November 9, 2026 although the company has not confirmed it, any FDA communication ahead of January 21, 2027, and the topline readout for z-basivarsen in the first quarter of 2027.

FAQs

Q: Why is Dyne Therapeutics down in premarket trading on November 4, 2026?

A: The stock fell 8.98% to USD 16.43. No company announcement dated November 2 to November 4, 2026 was identified, so the move appears to reflect trading sentiment.

Q: When is the FDA decision date for z-rostudirsen?

A: The FDA set a target action date of January 21, 2027 after accepting the application with Priority Review in July 2026.

Q: How much cash does Dyne have?

A: The company reported USD 898.5 million at June 30, 2026 and said that, with its July 2026 offering, it expects funding into the second quarter of 2028.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.